Pharma industry executives told Politico they are still processing the four executive orders released on July 24, as they are worried the new rules will hinder innovation and drug availability.
BIO, a lobby that advocates for small biotech companies, told Politico new regulations will affect its drugmakers the most, as the prices of their expensive cancer and chronic disease drugs would change greatly.
“The president’s plan to import policies from socialized health care systems abroad is disrupting our work [on COVID-19 therapies] and diverting our focus away from those life-saving efforts,” a spokesperson for the PhMA lobby told Politico. “We remain willing to discuss ways to lower costs for patients at the pharmacy counter. However, we remain steadfastly opposed to policies that would allow foreign governments to set prices for medicines in the United States.”
During a July 28 news conference, President Trump told drugmakers they have a month to propose a better alternative to the new rules.
“The White House has been more than accommodating in attempts to schedule this meeting,” a White House official told Politico.
More articles on pharmacy:
Walgreens CEO steps down
AstraZeneca, Daiichi Sankyo partner in $6B cancer drug deal
AstraZeneca to pay Emergent $174M to expand production of COVID-19 vaccine candidate
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.